Products

MRICD pioneered many of the techniques that have become standards in the life-science studies of chemical agents.

MRICD's demonstrated skill in developing innovative solutions to complex technical problems has resulted in our ability to move from basic research findings to applications for medical treatment. All currently available medical countermeasures against chemical warfare agents, to include cholinolytic antidotes, oxime enzyme reactivators, carbamate pretreatments, benzodiazepine anticonvulsants, reactive skin decontaminants and topical skin protectants, were either fully developed at the MRICD or had most preclinical efficacy testing done at the MRICD prior to FDA licensure.

MRICD is strengthening the defense of our nation by rendering chemical and biochemical threats medically harmless.

• A History of Providing Medical Protection for the Warfighter

  • 1980's

    • 
      MARK I Nerve Agent Antidote Kit

      FDA approval and fielding of MARK I

  • 1990's

    • 
      TestMate® Cholinesterase Kit

      Measures blood enzymes erythrocyte AChE and/or plasma cholinesterase, providing detection of nerve agent exposure in less than 4 minutes
    • 
      Convulsant Antidote Nerve Agent (CANA)

      Fielding of diazepam in the CANA autoinjector

  • 2000's

    • 
      Reactive Skin Decontamination Lotion

      Conducted decisive studies on the efficacy of RSDL
    • 
      ATNAA

      FDA approval of Antidote Treatment Nerve Agent Autoinjector
    • 
      Pyridostigmine

      FDA approval of pyridostigmine bromide under the "Animal Efficacy Rule" to increase survival after soman exposure
    • 
      SERPACWA

      FDA approval of Skin Exposure Reduction Paste Against Chemical Warfare Agents

• MRICD's Solutions for CBRNE Threats

  • 2000's

    • 
      Midazolam

      AAS (Advanced Anticonvulsant System)

  • 2010's

    • 
      PBA/FGA Treatment Guidelines

      Provided subject matter expertise in guideline development
    • 
      Nerve Agent Treatment Systems (new reactivators​ and adjunct treatments)

      Improved Nerve Agent Treatment System: Centrally Acting (INATS -CA)
      Reactive Nerve Agent Treatment System (RNATS)
    • 
      ChemDX

      An ultra-portable, low complexity in vitro diagnostics system to provide indication of CWA exposure on the battlefield
    • 
      Naloxone Autoinjector

      Critical efficacy studies